- Home
- MYNZ vs CDIO Comparison
MYNZ vs CDIO Comparison
Compare MYNZ & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- CDIO
- Stock Information
- Founded
- MYNZ 2021
- CDIO 2017
- Country
- MYNZ Germany
- CDIO United States
- Employees
- MYNZ N/A
- CDIO N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- MYNZ Health Care
- CDIO Health Care
- Exchange
- MYNZ Nasdaq
- CDIO Nasdaq
- Market Cap
- MYNZ 7.9M
- CDIO 6.4M
- IPO Year
- MYNZ 2021
- CDIO N/A
- Fundamental
- Price
- MYNZ $1.63
- CDIO $3.75
- Analyst Decision
- MYNZ Buy
- CDIO
- Analyst Count
- MYNZ 2
- CDIO 0
- Target Price
- MYNZ $14.00
- CDIO N/A
- AVG Volume (30 Days)
- MYNZ 107.2K
- CDIO 29.6K
- Earning Date
- MYNZ 10-21-2025
- CDIO 08-14-2025
- Dividend Yield
- MYNZ N/A
- CDIO N/A
- EPS Growth
- MYNZ N/A
- CDIO N/A
- EPS
- MYNZ N/A
- CDIO N/A
- Revenue
- MYNZ $893,991.00
- CDIO $19,507.00
- Revenue This Year
- MYNZ $26.06
- CDIO $1,434.82
- Revenue Next Year
- MYNZ $4.97
- CDIO $4,661.91
- P/E Ratio
- MYNZ N/A
- CDIO N/A
- Revenue Growth
- MYNZ N/A
- CDIO N/A
- 52 Week Low
- MYNZ $1.30
- CDIO $3.22
- 52 Week High
- MYNZ $16.04
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- MYNZ 45.49
- CDIO 47.61
- Support Level
- MYNZ $1.70
- CDIO $3.62
- Resistance Level
- MYNZ $1.79
- CDIO $3.99
- Average True Range (ATR)
- MYNZ 0.11
- CDIO 0.23
- MACD
- MYNZ -0.00
- CDIO 0.03
- Stochastic Oscillator
- MYNZ 14.06
- CDIO 66.67
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.